Alleviating cancer drug toxicity by inhibiting a bacterial enzyme

Bret D. Wallace, Hongwei Wang, Kimberly T. Lane, John E. Scott, Jillian Orans, Ja Seol Koo, Madhukumar Venkatesh, Christian Jobin, Li An Yeh, Sridhar Mani, Matthew R. Redinbo

Research output: Contribution to journalArticlepeer-review

719 Citations (Scopus)


The dose-limiting side effect of the common colon cancer chemotherapeutic CPT-11 is severe diarrhea caused by symbiotic bacterial β-glucuronidases that reactivate the drug in the gut. We sought to target these enzymes without killing the commensal bacteria essential for human health. Potent bacterial β-glucuronidase inhibitors were identified by high-throughput screening and shown to have no effect on the orthologous mammalian enzyme. Crystal structures established that selectivity was based on a loop unique to bacterial β-glucuronidases. Inhibitors were highly effective against the enzyme target in living aerobic and anaerobic bacteria, but did not kill the bacteria or harm mammalian cells. Finally, oral administration of an inhibitor protected mice from CPT-11-induced toxicity. Thus, drugs may be designed to inhibit undesirable enzyme activities in essential microbial symbiotes to enhance chemotherapeutic efficacy.

Original languageEnglish
Pages (from-to)831-835
Number of pages5
Issue number6005
Publication statusPublished - 2010 Nov 5
Externally publishedYes

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Alleviating cancer drug toxicity by inhibiting a bacterial enzyme'. Together they form a unique fingerprint.

Cite this